Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Glenmark Pharmaceuticals Limited
WARNING LETTER
•Glenmark Pharmaceuticals Limited•April 20, 2019

Glenmark Pharmaceuticals Limited – FDA Warning Letter, Apr 20, 2019

Record Details

The FDA issued a Warning Letter to Glenmark Pharmaceuticals Limited following an inspection from April 15-20, 2019, at their Baddi Solan, Himachal Pradesh facility. The letter cites significant violations of current good manufacturing practice (CGMP) regulations (21 CFR parts 210 and 211), rendering their drug products adulterated.

Key violations include: 1. **Failure to thoroughly investigate discrepancies (21 CFR 211.192):** * Inadequate investigation of multiple grittiness complaints for topical (b)(4) cream USP, (b)(4)%, an ongoing issue since 2010. The firm's proposed reformulation and recall were not timely, and data supporting the new formulation's robustness was insufficient. * Failure to adequately investigate multiple temperature excursions during shipping of drug products, including (b)(4) cream USP and (b)(4) USP, leading to distribution of products exposed to temperatures outside labeled conditions. Risk assessment for marketed batches was inadequate, and new shipping practices were not timely. * Inadequate investigation of multiple Out-of-Specification (OOS) test results for critical product attributes like (b)(4) and (b)(4), failing to determine root causes or ensure effective CAPA. * Failure to adequately investigate over 70 consumer complaints regarding punctures, cracks, and holes in (

Company
Glenmark Pharmaceuticals Limited
Inspection date
April 20, 2019
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Francis Godwin (Director)
View Company Profile

ID · 564e19c0-f3be-4691-97d4-7b89ca5fceb2

Violation Codes8
21 U.S.C. 351(a)(2)(B)21 CFR 21021 CFR 21121 CFR 211.192FD&C Act 501(a)(2)(B)FD&C Act 801(a)(3)21 U.S.C. 381(a)(3)21 U.S.C. 356C(b)

Full citation text and observation details available on the Dashboard.

Other documents for Glenmark Pharmaceuticals Limited
  • 483 - 2022-06-22June 22, 2022
  • WARNING_LETTER - 2022-05-20May 20, 2022
  • 483 - 2019-04-20April 20, 2019
  • 483 - 2017-11-11November 11, 2017

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Glenmark Pharmaceuticals Limited
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.